ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/mTORC1-inhibitor
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/mTORC1-inhibitor
13
trial(s) found.
NCT07369505
Advanced
Phase 1
Recruiting
A Phase 1b, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics of Sapu003 in Advanced mTOR-sensitive Solid Tumors (With or Without Exemestane) (
SP-03-B101
)
aromatase inhibitor
mTORC1/mTORC2 inhibitor
Breast cancer
Clear cell renal cell carcinoma
Hepatocellular carcinoma
Neuroendocrine tumour
SA
5042 - Bedford Park - Southern Oncology Clinical Research Unit
NCT07062965
Advanced
Phase 3
Recruiting
An Interventional, Open-Label, Randomized, Multicenter, Phase 3 Study of PF-07248144 Plus Fulvestrant Compared to Investigator's Choice of Therapy in Adult Participants With Hormone Receptor-Positive, HER2-Negative Advanced/Metastatic Breast Cancer Whose Disease Progressed After Prior CDK4/6 Inhibitor-based Therapy (
C4551002
)
KAT6A/B inhibitor
KAT6 inhibitor
selective estrogen receptor degrader
+ mTORC1 inhibitor
Breast cancer
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3021 - St Albans - Western Health - Sunshine Hospital
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
NCT06943755
Advanced
Phase 2 / Phase 3
Recruiting
A Phase 2/3, Multicenter, Randomized Open-Label Study of Zanzalintinib vs Everolimus in Participants With Previously Treated, Unresectable, Locally Advanced or Metastatic Neuroendocrine Tumors (
STELLAR-311
)
MET/VEGFR2/AXL/MER inhibitor
mTORC1 inhibitor
Pancreatic neuroendocrine tumour
NSW
2065 - St Leonards - GenesisCare North Shore Private Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
SA
5011 - Woodville South - The Queen Elizabeth Hospital
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT06757634
Advanced
Phase 3
Recruiting
VIKTORIA-2: A Randomized, Open-Label, Phase 3 Study Evaluating Efficacy and Safety of Gedatolisib With Endocrine Therapy and Palbociclib vs Endocrine Therapy and Ribociclib as First-Line Treatment in Patients With HR-Positive and HER2-Negative Advanced Breast Cancer (
CELC-G-302
)
CDK4/6 inhibitor
pan-PI3K/mTORC1/mTORC2 inhibitor
Breast cancer
NSW
2076 - Wahroonga - Sydney Adventist Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
QLD
4215 - Southport - ICON Cancer Care
SA
5000 - South Australia - GenesisCare St Andrews Hospital
5011 - Woodville South - The Queen Elizabeth Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06208657
Paed
Phase 1 / Phase 2
Recruiting
Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer (
OPTIMISE
)
Irinotecan
Nivolumab
PI3K alpha inhibitor
PI3K delta inhibitor
PI3K inhibitor
Paxalisib
Relatlimab
Temozolomide
alkylating agent
anti-LAG3 monoclonal antibody
anti-PD-1 monoclonal antibody
cancer therapy
cancer therapy,LAG3-targeting
cancer therapy,PD-1-targeting
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,PI3K-targeting
cancer therapy,PI3K delta-targeting
cancer therapy,PI3Kalpha-targeting
cancer therapy,mTOR-targeting
cancer therapy,mTORC1-targeting
cancer therapy,mTORC2-targeting
cytotoxic chemotherapy
dual PI3K/mTOR inhibitor
immune checkpoint blockade
immune checkpoint blockade,LAG3-targeting
immune checkpoint blockade,PD-1-targeting
immuno-oncology therapy,LAG3-targeting
immuno-oncology therapy,PD-1-targeting
mTORC1/mTORC2 inhibitor
mTORC1 inhibitor
mTORC2 inhibitor
mTOR inhibitor
topoisomerase inhibitor
+ mTORC1/mTORC2 inhibitor
Cancer
Central nervous system cancer
Solid tumour
NSW
2031 - Randwick - Sydney Children's Hospital
2145 - Westmead - The Children's Hospital at Westmead
2305 - New Lambton Heights - John Hunter Children's Hospital
VIC
3052 - Parkville - Royal Children's Hospital Melbourne
3168 - Clayton - Monash Children's Hospital
QLD
4101 - South Brisbane - Queensland Children's Hospital
SA
5006 - North Adelaide - Women's and Children's Hospital-Adelaide Cancer Centre
WA
6009 - Perth - Perth Children's Hospital
TAS
7000 - Hobart - Royal Hobart Hospital
NCT05843253
Paed
Phase 2
Recruiting
Phase 2 Study of Ribociclib-Containing Post-Radiotherapy Combinations in Pediatric and Young Adult Patients Newly Diagnosed With High-Grade Glioma, Including Diffuse Intrinsic Pontine Glioma: Ribociclib and Everolimus for HGG/DIPG Which Harbor Alterations of the Cell Cycle and/or PI3K/mTOR Pathways AND Ribociclib and Temozolomide for DHG, H3G34-mutant (
CONNECT-TarGeT-A
)
CDK4/6 inhibitor
alkylating agent
mTORC1 inhibitor
radiotherapy
Anaplastic astrocytoma
Central nervous system cancer
Diffuse hemispheric glioma
Diffuse intrinsic pontine glioma
Glioblastoma
Glioma
H3K27M-mutant glioma
High-grade glioma
NSW
2031 - Randwick - Sydney Children's Hospital
VIC
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
QLD
4101 - South Brisbane - Queensland Children's Hospital
WA
6009 - Perth - Perth Children's Hospital
NZ
NZ.1023 - Grafton - Starship Children's Hospital
NCT05508906
Advanced
Phase 1
Recruiting
A Phase 1b Open-Label Multicenter Study of OP-1250 (Palazestrant) in Combination With the CDK4/6 Inhibitor Ribociclib, With the PI3K Inhibitor Alpelisib, With the mTOR Inhibitor Everolimus, or With CDK4 Inhibitor Atirmociclib in Adult Subjects With Advanced and/or Metastatic ER Positive, HER2 Negative Breast Cancer (
OP-1250-003
)
CDK4/6 inhibitor
CDK4 selective inhibitor
PI3K alpha inhibitor
complete estrogen receptor antagonist
mTORC1 inhibitor
Breast cancer
ER-positive breast cancer
HER2-negative breast cancer
NSW
2109 - North Ryde - Macquarie University Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT04802759
Advanced
Phase 1 / Phase 2
Recruiting
A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Breast Cancer (MORPHEUS-BREAST CANCER) (
CO42867
)
AKT inhibitor
Abemaciclib
Atezolizumab
CDK4/6 inhibitor
CDK4 inhibitor
CDK6 inhibitor
CDK7 inhibitor
ER degrader
Everolimus
Giredestrant
Inavolisib
Ipatasertib
PI3K alpha inhibitor
Palbociclib
Pertuzumab
Ribociclib
Samuraciclib
anti-ERBB2 monoclonal antibody
anti-ERBB2 monoclonal antibody,dimerization inhibitor
anti-PD-L1 monoclonal antibody
cancer therapy
cancer therapy,AKT-targeting
cancer therapy,CDK4-targeting
cancer therapy,CDK6-targeting
cancer therapy,CDK7-targeting
cancer therapy,ERBB2-targeting
cancer therapy,ESR1-targeting
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,PD-L1-targeting
cancer therapy,PI3Kalpha-targeting
cancer therapy,mTOR-targeting
cancer therapy,mTORC1-targeting
endocrine therapy
endocrine therapy,oestrogen axis-targeting
immune checkpoint blockade
immune checkpoint blockade,PD-L1-targeting
immuno-oncology therapy,ERBB2-targeting
immuno-oncology therapy,PD-L1-targeting
mTORC1 inhibitor
mTOR inhibitor
oestrogen receptor-targeting therapy
pan-AKT inhibitor
selective estrogen receptor degrader
+ mTORC1 inhibitor
Breast cancer
ER-positive breast cancer
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3199 - Frankston - Peninsula Health Frankston Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Linear Clinical Research
NCT03970447
Radonc
Phase 2 / Phase 3
Recruiting
GBM AGILE: Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent GBM (
GBM-AGILE
)
ATM inhibitor
AZD1390
Dianhydrogalactitol
FGFR1/2/3 inhibitor
FGFR1 inhibitor
FGFR2 inhibitor
FGFR3 inhibitor
FGFR4 inhibitor
FGFR inhibitor
KIT/PDGFR/RET/VEGFR/FGFR inhibitor
KIT inhibitor
KIT inhibitor,first generation
Lomustine
PDGFR inhibitor
PI3K alpha inhibitor
PI3K delta inhibitor
PI3K inhibitor
Paxalisib
Pegargiminase
RET inhibitor
Radiotherapy
Regorafenib
Temozolomide
Troriluzole
VEGFR inhibitor
alkylating agent
arginine deiminase-polyethylene glycol conjugate
cancer therapy
cancer therapy,ATM-targeting
cancer therapy,FGFR-targeting
cancer therapy,FGFR1-targeting
cancer therapy,FGFR1/2/3-targeting
cancer therapy,FGFR2-targeting
cancer therapy,FGFR3-targeting
cancer therapy,FGFR4-targeting
cancer therapy,KIT-targeting
cancer therapy,PDGFR-targeting
cancer therapy,PI3K-targeting
cancer therapy,PI3K delta-targeting
cancer therapy,PI3Kalpha-targeting
cancer therapy,RET-targeting
cancer therapy,VEGFR-targeting
cancer therapy,mTOR-targeting
cancer therapy,mTORC1-targeting
cancer therapy,mTORC2-targeting
cytotoxic chemotherapy
dual PI3K/mTOR inhibitor
glutamate modulator
mTORC1/mTORC2 inhibitor
mTORC1 inhibitor
mTORC2 inhibitor
mTOR inhibitor
pan-FGFR inhibitor
pan-FGFR inhibitor,reversible
+ mTORC1/mTORC2 inhibitor
Glioblastoma
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
SA
5042 - Bedford Park - Flinders Medical Centre
ACTRN12624001340527
Advanced
Phase 1
Recruiting
A Phase 1b, Multi-centre, Open-label, Randomized Study to Evaluate the Safety, Tolerability, and Clinical Activity of Combining Paxalisib with Olaparib or Pembrolizumab/Chemotherapy in Patients with Advanced Breast Cancer (
PaxPlus-ABC
)
PARP1/2 inhibitor
anti-PD-1 monoclonal antibody
dual PI3K/mTOR inhibitor
+ mTORC1/mTORC2 inhibitor
Breast cancer
NSW
2290 - Gateshead - Genesis Cancer Care, Lake Macquarie Private Hospital
ACT
2605 - Garran - The Canberra Hospital
ACTRN12611001224910
Haem
Phase 4
Not yet recruiting
A prospective, open label, controlled, multicentre trial to assess the effect of an induction regimen of Thymoglobulin (Registered Trademark) compared with Simulect (Registered Trademark) with Tacrolimus, Mycophenolic acid and corticosteroids, followed by withdrawal of Tacrolimus for Sirolimus on the development of regulatory T cells in kidney transplant recipients of donation after cardiac death donor kidneys (
RESTORE
)
mTORC1/mTORC2 inhibitor
Cancer
ACTRN12610001031055
Haem
Phase 1 / Phase 2
Recruiting
A Phase Ib/II Clinical Evaluation of the Safety of Combining the mTOR inhibitor Everolimus with 5-Azacitidine in AML
DNA methyltransferase inhibitor
antimetabolite
mTORC1 inhibitor
Acute myeloid leukaemia
ACTRN12607000218493
Advanced
Phase 2
Recruiting
Phase II Study Evaluating Efficacy and Safety of Everolimus with Letrozole for Management of Advanced (unresectable or metastatic) Non Small Cell Lung Cancer (NSCLC) after Failure of Platinum-Based Treatment
aromatase inhibitor
mTORC1 inhibitor
Non-small cell lung cancer
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (12)
Not yet recruiting (1)
Recruitment Country and State
SA (7)
NSW (7)
VIC (6)
WA (6)
QLD (5)
TAS (1)
NZ (1)
ACT (1)
Phase
Phase 1 (3)
Phase 1 / Phase 2 (3)
Phase 2 (2)
Phase 2 / Phase 3 (2)
Phase 3 (2)
Phase 4 (1)
Trial Type
Advanced (8)
Paed (2)
Haem (2)
Paed (1)
Radonc (1)
Cancer Therapy Class
mTOR
100%
mTORC1
100%
mTORC2
46%
oestrogen axis
46%
PI3Kalpha
46%
ER
31%
CDK4
31%
CDK6
31%
PI3K
31%
PD-1/PD-L1
23%
PI3K delta
23%
PD-1
15%
KAT6
8%
KAT6A
8%
AXL
8%
MER
8%
MET
8%
VEGFR2
8%
LAG3
8%
CDK4 selective
8%
AKT
8%
CDK7
8%
ERBB2
8%
PD-L1
8%
ATM
8%
FGFR
8%
FGFR1
8%
FGFR1/2/3
8%
FGFR2
8%
FGFR3
8%
FGFR4
8%
KIT
8%
PDGFR
8%
RET
8%
VEGFR
8%
PARP
8%
DNA methyltransferase
8%
Facility
3000 - Melbourne - Peter MacCallum Cancer Centre (4)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (2)
5011 - Woodville South - The Queen Elizabeth Hospital (2)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (2)
2031 - Randwick - Sydney Children's Hospital (2)
4101 - South Brisbane - Queensland Children's Hospital (2)
6009 - Perth - Perth Children's Hospital (2)
5042 - Bedford Park - Flinders Medical Centre (2)
5042 - Bedford Park - Southern Oncology Clinical Research Unit (1)
3021 - St Albans - Western Health - Sunshine Hospital (1)
5037 - Kurralta Park - Icon Cancer Centre Adelaide (1)
2065 - St Leonards - GenesisCare North Shore Private Hospital (1)
3168 - Clayton - Monash Medical Centre (1)
6150 - Murdoch - Fiona Stanley Hospital (1)
2076 - Wahroonga - Sydney Adventist Hospital (1)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (1)
4215 - Southport - ICON Cancer Care (1)
5000 - South Australia - GenesisCare St Andrews Hospital (1)
2145 - Westmead - The Children's Hospital at Westmead (1)
2305 - New Lambton Heights - John Hunter Children's Hospital (1)
3052 - Parkville - Royal Children's Hospital Melbourne (1)
3168 - Clayton - Monash Children's Hospital (1)
5006 - North Adelaide - Women's and Children's Hospital-Adelaide Cancer Centre (1)
7000 - Hobart - Royal Hobart Hospital (1)
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health (1)
NZ.1023 - Grafton - Starship Children's Hospital (1)
2109 - North Ryde - Macquarie University Hospital (1)
3199 - Frankston - Peninsula Health Frankston Hospital (1)
6009 - Nedlands - Linear Clinical Research (1)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (1)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (1)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (1)
2290 - Gateshead - Genesis Cancer Care, Lake Macquarie Private Hospital (1)
2605 - Garran - The Canberra Hospital (1)
Cancer Type
Cancer
Solid tumour
Breast cancer
Central nervous system cancer
Neurological cancer
Gastrointestinal cancer
Neuroendocrine tumour
Upper gastrointestinal cancer
Glioblastoma
Glioma
High-grade glioma
Malignant glioma
Breast adenocarcinoma
ER-positive breast cancer
HR-positive breast cancer
Clear cell renal cell carcinoma
Hepatobiliary cancer
Hepatocellular carcinoma
Kidney cancer
Urogenital cancer
Gastro-entero-pancreatic neuroendocrine tumour
Pancreatic cancer
Pancreatic neuroendocrine tumour
Pancreatobiliary cancer
Anaplastic astrocytoma
Diffuse hemispheric glioma
Diffuse intrinsic pontine glioma
H3K27M-mutant glioma
HER2-negative breast cancer
Acute myeloid leukaemia
Haematological malignancy
Leukaemia
Myeloid leukaemia
Lung cancer
Non-small cell lung cancer
Respiratory tract cancer
Thoracic cancer
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy